## Core Concept
Myasthenia Gravis (MG) is an autoimmune disease characterized by weakness and rapid fatigue of the muscles under voluntary control. It is caused by a breakdown in the normal communication between nerves and muscles. The underlying pharmacological principle being tested here involves the receptors at the neuromuscular junction.

## Why the Correct Answer is Right
The correct answer involves the blockade of **nicotinic acetylcholine receptors (nAChRs)**. In Myasthenia Gravis, the immune system produces antibodies that block or destroy nicotinic acetylcholine receptors at the junction between the nerve and muscle, known as the neuromuscular junction. This reduces the number of available receptors for acetylcholine to bind, thereby impairing the nerve's ability to communicate with the muscle. As a result, the muscle cannot contract effectively, leading to muscle weakness.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because it does not accurately represent the receptors involved in Myasthenia Gravis.
- **Option B:** This option is incorrect as it does not specify the correct type of receptors blocked in MG.
- **Option C:** While muscarinic receptors are another type of acetylcholine receptor, they are not the primary receptors involved in the neuromuscular transmission affected in Myasthenia Gravis.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that Myasthenia Gravis is often treated with medications that increase neuromuscular transmission, such as anticholinesterases (e.g., pyridostigmine), which work by preventing the breakdown of acetylcholine, thereby increasing its availability to bind to the remaining functional nicotinic receptors.

## Correct Answer: D. nicotinic acetylcholine receptors.